View source for Access to medicines

<div class="wiki-language-nav" style="padding:0.75em; border:1px solid #b5c8cd; border-radius:0.5em; margin-bottom:1em;">[[Access to medicines|English]] · [[Access to medicines/uk|Українська]] · [[Access to medicines/es|Español]] · [[Access to medicines/fr|Français]] · [[Access to medicines/de|Deutsch]] · [[Access to medicines/pt|Português]]</div>
Access to medicines is a distinct question from whether a medicine exists or has a recognized pharmacological action. Research can examine the legal, organizational and product-related conditions under which people can obtain appropriate care.

Andrii Gudzenko's 2021 study examines availability for medicines identified by three international nonproprietary names in the context of mental-health care for affected populations. It links availability analysis with clinical-pharmacological and legal classifications. Its comparative conclusion belongs to that study and period; it should not be converted into a universal ranking of antidepressants or a recommendation for individual treatment.

For a scientific wiki, the study is useful as an example of the relationship between pharmaceutical provision, patient groups and regulatory categories. Appropriate prescribing remains an individual clinical decision. Related topics: socially oriented pharmaceutical care, pharmaceutical law, pharmacoeconomic analysis and medicine classification.

== Source ==
Gudzenko, A. (2021). Determining The Availability of Antidepressants for The Pharmacotherapy of Mental Disorders Among Victims (Experimental Study). SSP Modern Pharmacy and Medicine, 1(2).

[https://doi.org/10.53933/sspmpm.v1i2.25 Article] · [https://archive.sreif.us/index.php/mpm/article/view/25 Journal record]

[[Category:Research concepts]]

See also: [[Terms and concepts|Terms and concepts index]] · [[Journal research map]] · [[History and research foundations]].